These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 31300450)

  • 41. RET fusion as a novel driver of medullary thyroid carcinoma.
    Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ
    J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics and Survival Outcomes of Patients With Metastatic
    Hackshaw A; Fajardo O; Dafni U; Gelderblom H; Garrido P; Siena S; Taylor MH; Bordogna W; Nikolaidis C
    JCO Precis Oncol; 2024 Jan; 8(1):e2300334. PubMed ID: 38271655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
    Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
    Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.
    Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
    World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 46. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
    Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report.
    Xu X; Wang H; Yu Z; Chen X
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1825-1827. PubMed ID: 35364706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
    Ju YS; Lee WC; Shin JY; Lee S; Bleazard T; Won JK; Kim YT; Kim JI; Kang JH; Seo JS
    Genome Res; 2012 Mar; 22(3):436-45. PubMed ID: 22194472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
    Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
    Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
    Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
    Michels S; Scheel AH; Scheffler M; Schultheis AM; Gautschi O; Aebersold F; Diebold J; Pall G; Rothschild S; Bubendorf L; Hartmann W; Heukamp L; Schildhaus HU; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Fischer R; Nogovà L; Mattonet C; Hein R; Adams A; Gerigk U; Schulte W; Lüders H; Grohé C; Graeven U; Müller-Naendrup C; Draube A; Kambartel KO; Krüger S; Schulze-Olden S; Serke M; Engel-Riedel W; Kaminsky B; Randerath W; Merkelbach-Bruse S; Büttner R; Wolf J
    J Thorac Oncol; 2016 Jan; 11(1):122-7. PubMed ID: 26762747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
    Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
    Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
    Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?
    Skálová A; Ptáková N; Santana T; Agaimy A; Ihrler S; Uro-Coste E; Thompson LDR; Bishop JA; Baněčkova M; Rupp NJ; Morbini P; de Sanctis S; Schiavo-Lena M; Vanecek T; Michal M; Leivo I
    Am J Surg Pathol; 2019 Oct; 43(10):1303-1313. PubMed ID: 31162284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
    Wijesinghe P; Bepler G; Bollig-Fischer A
    J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Characteristics and Molecular Patterns of
    Zhang K; Chen H; Wang Y; Yang L; Zhou C; Yin W; Wang G; Mao X; Xiang J; Li B; Zhang T; Fei S
    Oncol Res; 2019 May; 27(5):575-582. PubMed ID: 30131091
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.